Non-small-cell lung cancer
Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Rafael Rosell(Hospital Universitario Dexeus), Antônio Rossi(Università Campus Bio-Medico), David P. Carbone(Vanderbilt University), Tony Mok(Chinese University of Hong Kong), Juliana Guarize(European Institute of Oncology), Lorenzo Spaggiari(European Institute of Oncology), Niki Karachaliou(Institut Català d'Oncologia), Francesco Petrella(European Institute of Oncology)
Cited by 1,090
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k